This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Mani, S. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Mani, S.

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs

Authors' Affiliations: ¹ Albert Einstein Cancer Center, Departments of ² Medicine, ³ Pathology, and ⁴ Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York; ⁵ Bristol Myers Squibb Co. Wallingford, Connecticut; ⁶ Johns Hopkins University, Baltimore, Maryland; ⁷ University of Kansas, Lawrence, Kansas; and ⁸ University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Requests for reprints: Sridhar Mani, Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Chanin 302D-1, Bronx, NY 10461. Phone: 718-430-2871; Fax: 718-904-2892; E-mail: smani{at}montefiore.org.

Purpose: Variations in biotransformation and elimination of microtubule-binding drugs are a major cause of unpredictable side effects during cancer therapy. Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.

Experimental Design: In vitro RNA-, protein-, and transcription-based assays in multiple cell lines derived from hepatocytes and PXR wild-type and null mouse studies were employed to show the effects of ketoconazole and its analogues on ligand-activated PXR-mediated gene transcription and translation.

Results: The transcriptional activation of genes regulating biotransformation and transport by the liganded human nuclear xenobiotic receptor, PXR, was inhibited by the commonly used antifungal ketoconazole and related azole analogs. Mutations at the AF-2 surface of the human PXR ligand-binding domain indicate that ketoconazole may interact with specific residues outside the ligand-binding pocket. Furthermore, in contrast to that observed in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel.

Conclusions: These studies show that some azole compounds repress the coordinated activation of genes involved in drug metabolism by blocking PXR activation. Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogues may also serve to preserve paclitaxel blood levels on chronic dosing of drugs. Our observations may facilitate new strategies to improve the clinical efficacy of drugs and to reduce therapeutic side effects.

This article has been cited by other articles:

				R. L. Oostendorp, A. Huitema, H. Rosing, R. S. Jansen, R. ter Heine, M. Keessen, J. H. Beijnen, and J. H.M. Schellens Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors Clin. Cancer Res., June 15, 2009; 15(12): 4228 - 4233. [Abstract] [Full Text] [PDF]

				D. G. Teotico, J. J. Bischof, L. Peng, S. A. Kliewer, and M. R. Redinbo Structural Basis of Human Pregnane X Receptor Activation by the Hops Constituent Colupulone Mol. Pharmacol., December 1, 2008; 74(6): 1512 - 1520. [Abstract] [Full Text] [PDF]

				S. Ekins, V. Kholodovych, N. Ai, M. Sinz, J. Gal, L. Gera, W. J. Welsh, K. Bachmann, and S. Mani Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists Mol. Pharmacol., September 1, 2008; 74(3): 662 - 672. [Abstract] [Full Text] [PDF]

				D. Gupta, M. Venkatesh, H. Wang, S. Kim, M. Sinz, G. L. Goldberg, K. Whitney, C. Longley, and S. Mani Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer Clin. Cancer Res., September 1, 2008; 14(17): 5332 - 5340. [Abstract] [Full Text] [PDF]

				R. J. Kavlock, G. Ankley, J. Blancato, M. Breen, R. Conolly, D. Dix, K. Houck, E. Hubal, R. Judson, J. Rabinowitz, et al. Computational Toxicology--A State of the Science Mini Review Toxicol. Sci., May 1, 2008; 103(1): 14 - 27. [Abstract] [Full Text] [PDF]

				H. Wang, H. Li, L. B. Moore, M. D. L. Johnson, J. M. Maglich, B. Goodwin, O. R. R. Ittoop, B. Wisely, K. Creech, D. J. Parks, et al. The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor Mol. Endocrinol., April 1, 2008; 22(4): 838 - 857. [Abstract] [Full Text] [PDF]

				L. Svecova, R. Vrzal, L. Burysek, E. Anzenbacherova, L. Cerveny, J. Grim, F. Trejtnar, J. Kunes, M. Pour, F. Staud, et al. Azole Antimycotics Differentially Affect Rifampicin-Induced Pregnane X Receptor-Mediated CYP3A4 Gene Expression Drug Metab. Dispos., February 1, 2008; 36(2): 339 - 348. [Abstract] [Full Text] [PDF]

				S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al. Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603. [Abstract] [Full Text] [PDF]